The Pediatric HIV Nutrition Study in Uganda

Child Nutrition Disorders Clinical Trial

— NOURISH  

Official title:

The Role of Nutrition as a Determinant of Immune Function and Pharmacological Outcome Amongst HIV Infected Malnourished Children in Uganda

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02421302
• Other study ID #: ST/0110/15
• Secondary ID: ST/0110/15
• Status: Recruiting
• Phase: N/A
• First received: February 18, 2015
• Last updated: April 15, 2015
• Start date: February 2015
• Est. completion date: April 2016

Study information

• Verified date: April 2015
• Source: Makerere University
• Contact: Judy Orikiiriza, MMED
• Phone: +256312307000
• Email: jorikiiriza[@]idi.co.ug
• Is FDA regulated: No
• Health authority: Uganda: National Council for Science and Technology
• Study type: Interventional

Clinical Trial Summary

This will be cohort study design with both qualitative and quantitative methods of data collection. The investigators are aiming to study 64 HIV positive children as healthy controls either initiating ART or already on ART and 86 malnourished HIV infected children on ART or naïve initiating ART and RUTF aged between 6 months to 12 years. Primary carers will be asked to provide informed consent whereby the children and primary carers will be enrolled into the study and followed up for 12 weeks.

Description:

BACKGROUND: Malnutrition and Human Immunodeficiency Virus (HIV) infection are intimately linked and present a serious health challenge in Africa. Approximately 30-50% of children in Uganda with severe acute malnutrition (SAM) are HIV infected. Studies on nutrition as a determinant of immune response and drug metabolism in malnourished children are unknown.

GAP: Clinicians have noted that certain patients deteriorate after starting ART and nutritional supplementation despite viralogical suppression and immunological improvement with a paradoxical emergence of certain opportunistic infections, electrolyte derangement and malnutrition hence IRIS or re-feeding syndrome (RF). There is paucity of data on nutrition as a determinant of immune and pharmacological response amongst HIV infected malnourished children despite malnutrition being common.

HYPOTHESIS: Well-nourished HIV infected children ART naïve or experienced will have a better nutritional, clinical, immunological and pharmacological outcome than malnourished children ART naïve or experienced.

METHODS: A cohort design studying 75 malnourished HIV infected children on ART and RUTF comparing them to 75 well-nourished children ART naive or experienced aged between 6 months to 12 years after primary carers have provided informed consent will be enrolled into the study and followed up for 12 weeks.

IMPACT: This study will endeavor to provide appropriate information that will enhance the management of malnourished HIV infected children in the context of both ART and RUTF and their impact on immune response and drug metabolism. The study will also generate other research questions that need to be addressed in order to optimize HIV services amongst malnourished children.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: April 2016
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 6 Months to 12 Years

Eligibility

Inclusion Criteria:

• HIV-infected children aged 6 months to 12 years, including Well Nourished (WN), Moderately Acute Malnutrition (MAM) and Severe Acute Malnutrition (SAM) patients initiating on ART within 2 weeks, whose carer is aged =18 years and has provided informed consent.

• Malnourished HIV-infected children aged 6 months to 12 years stabilized on ART for at least 6 months and initiating on RUTF, whose carer is aged =18 years and has provided informed consent.

Exclusion Criteria:

1. Previous enrollment in a nutritional therapeutic program in the last 3 months

2. Children involved in an on-going nutrition study

3. Children who have previously received the tuberculin skin test (TST) or mantoux or purified protein derivative (PPD) in the last 3 months.

4. Children with clinically suspected or confirmed malignancy

5. Children exhibiting any specific food intolerance

6. Children who are vomiting profusely (over 3 times daily)

7. Children living outside 50 km radius from Infectious Diseases Institute at Mulago, Kampala

8. Children whose carers do not want to disclose their home address.

9. Children whose cause of malnutrition is compounded by congenital malformations, chromosomal disorders, metabolic disorders, congenital immune disorders, cerebral palsy

10. Children with a severe disability limiting the possibility of investigations

11. Children who plan to leave the catchment area in the next 6 months

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Child Nutrition Disorders
• Nutrition Disorders

Intervention

Dietary Supplement:
• RUTF
This is ready-to-use-therapeutic-food

Locations

Country	Name	City	State
Uganda	Infectious Diseases Institute	Kampala
Uganda	Mildmay International Centre Kampala	Kampala

Sponsors (2)

Lead Sponsor	Collaborator
Infectious Diseases Institute	University of Dublin, Trinity College

Country where clinical trial is conducted

Uganda, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in numbers of circulating immune cell population and their capacity to release cytokines	Immune response	12 weeks	No
Secondary	Occurrence of Immune reconstitution inflammatory syndrome (IRIS)	Episodes of Opportunistic infections - Clinical outcomes	12 weeks	No
Secondary	Occurrence of re-feeding syndrome	Episodes of Opportunistic infections - Clinical outcomes	12 weeks	No
Secondary	Pharmacological: Cmax	Cmax of Non-nucleotide reverse - transcriptase inhibitors (NNRTI) and Protease Inhibitors(PIs) at 0weeks, 6weeks,12weeks	12 weeks	No
Secondary	Pharmacological: AUC	Area Under Curve (AUC) Time Frame: 0weeks, 6weeks, 12weeks for nevirapine and lopinvir/retonavir	12 weeks	No
Secondary	Number of participants with adverse events	Pharmacological: Number of participants with adverse events	12 weeks	Yes